Anabolic therapy of osteoporosis;Tratamiento anabólico en la osteoporosis

Medicina Clinica

Volumn 125, Issue 9, 2005, Pages

  Fernández García, Diego ^a   Alonso, Guillermo ^a   Muñoz Torres, Manuel ^a,b  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b NONE   (Spain)

Author keywords

Anabolic therapies; Osteoporosis; Parathyroid hormone; Strontium

Indexed keywords

ANABOLIC AGENT; FLUORIDE; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PARATHYROID HORMONE; SOMATOMEDIN C; STRONTIUM RANELATE;

DRUG EFFICACY; DRUG MECHANISM; HUMAN; OSSIFICATION; OSTEOPOROSIS; REVIEW;

EID: 26944473956     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13078782     Document Type: Review

References (68)

1. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002;359:2018-26.
2. Rubin MR, Bilezikian JP. New anabolic therapies in osteoporosis. Endocrinol Metabol Clin North Am. 2003;32:285-307.
3. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990;22;322:802-9.
4. Kleerekoper M, Peterson EL, Nelson DA, Phillips E, Schork MA, Tilley BC. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int. 1991;1:155-61.
5. Pak CY, Sakhaee K, Zerwekh JE, Parcel C, Peterson R, Johnson K. Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures. J Clin Endocrinol Metab. 1989;68:150-9.
6. Pak CY, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med. 1995;123:401-8.
7. Pak CY, Zerwekh JE, Antich PP, Bell NH, Singer FR. Slow-release sodium fluoride in osteoporosis. J Bone Miner Res. 1996;11:561-4.
8. Riggs BL, O'Fallon WM, Lane A, Hodgson SF, Wahner HW, Muhs J, et al. Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis. J Bone Miner Res. 1994;9:265-75.
9. Ringe JD, Kipshoven C, Coster A, Umbach R. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate. Osteoporos Int. 1999;9:171-8.
10. Reginster JY, Meurmans L, Zegels B, Rovati LC, Minne HW, Giacovelli G, et al. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial. Ann Intern Med. 1998;129:1-8.
11. Ringe JD, Dorst A, Kipshoven C, Rovati LC, Setnikar I. Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate. Osteoporos Int. 1998;8:47-52.
12. Reginster JY, Felsenberg D, Pavo I, Stepan J, Payer J, Resch H, et al. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. Osteoporos Int. 2003;14:741-9.
13. Lems WF, Jacobs JW, Bijlsma JW, van Veen GJ, Houben HH, Haanen HC, et al. Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? Ann Rheum Dis. 1997;56:357-63.
14. Ringe JD, Rovati LC. Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. Calcif Tissue Int. 2001;69:252-5
15. Muñoz-Torres M, Mezquita-Raya P, López-Rodríguez F, Torres-Vela E, de Dios Luna J, Escobar-Jiménez F. The contribution of IGF-I to skeletal integrity in postmenopausal women. Clin Endocrinol (Oxf). 2001;55:759-66.
16. Sugimoto T, Nishiyama K, Kuribayashi F, Chihara K. Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J Bone Miner Res. 1997;12:1272-9.
17. Bauer DC, Rosen CJ, Cauley J. Low serum IGF-I but not IGFBP-3 predicts hip and spine fracture: the study of osteoporotic fracture. J Bone Miner Res. 1998;23:561S.
18. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990;323:1-6.
19. Holloway L, Butterfield G, Hintz RL, Gesundheit N, Marcus R. Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. J Clin Endocrinol Metab. 1994;79:470-9.
20. Landin-Wilhelmsen KLL, Nilsson A. Growth hormone increases bone mineral content in postmenopausal osteoporosis. J Bone Miner Res. 2001;16Suppl 1:404F.
21. Landin-Wilhelmsen K, Nilsson A, Bosaeus I, Bengtsson BA. Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial. J Bone Miner Res. 2003;18:393-405.
22. Gillberg P, Mallmin H, Petren-Mallmin M, Ljunghall S, Nilsson AG. Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. J Clin Endocrinol Metab. 2002;87:4900-6.
23. Geusens P, Bouillon R, Broos P. Musculoskeletal effects of rhIGF-I/IGFBP-3 in hip fracture patients: results from a double-blind, placebo controlled phase II study. Bone. 1998;23:157S.
24. Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab. 2000;85:1137-42.
25. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet. 2000;355:2218-9.
26. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet. 2000;355:2185-8.
27. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 2000;283:3205-10.
28. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC. Geelong Osteoporosis Study. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med. 2002;162:537-40.
29. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286:1946-9.
30. Garrett IR, Gutiérrez G, Chen D. Statins stimulate bone formation by enhancing eNOS expression. J Bone Miner Res. 2001;16 Suppl 1:1018.
31. Chan MH, Mak TW, Chiu RW, Chow CC, Chan IH, Lam CW. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. J Clin Endocrinol Metab. 2001;86:4556-9.
32. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13:581-9.
33. Rejnmark L, Buus NH, Vestergaard P. Decreased bone turnover in postmenopausal women treated with statins: a cross-sectional study. J Bone Miner Res. 2001;16 Suppl 1:411A.
34. Cosman F, Nieves J, Zion M. Effects of short-term cerivastatin on bone turnover. J Bone Miner Res. 2001;16 Suppl 1:415A.
35. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, et al. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med. 2004;164:146-52.
36. Braga V, Gatti D, Rossini M. Association between lipid profile and bone mass in healthy men. J Bone Miner Res. 2001;16 Suppl 1:399A.
37. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in lschaemic Disease. Lancet. 2001;357:509-12.
38. Van Staa TP, Wegman S, De Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA. 2001;285:1850-5.
39. La Croix AZ, Cauley J, Jackson R. Does statin use reduce risk of fracture in postmenopausal women? Results from the Women's Health Initiative Observational Study (WHI-OS). J Bone Miner Res. 2000;6 Suppl 2:1066.
40. Boivin G, Deloffre P, Perrat B, Panczer G, Boudeulle M, Mauras Y, et al. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. J Bone Miner Res. 1996;9:1302-11.
41. Li L, Kruszewski FH, Punnonen K, Tucker RW, Yuspa SH, Hennings H. Strontium induces murine keratinocyte differentiation in vitro in the presence of serum and calcium. J Cell Physiol. 1993;154:643-53.
42. Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int. 2001;69:121-9.
43. Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev. 2001;81:239-97.
44. Brown EM. Is the calcium receptor a molecular target for the actions of strontium on bone? Osteoporos Int. 2003;14 Suppl 3:25-34.
45. Morohashi T, Sano T, Yamada S. Effects of strontium on calcium metabolism in rats. I. A distinction between the pharmacological and toxic doses. Jpn J Pharmacol. 1994;64:155-62.
46. Boivin G, Farlay D, Panczer G. Long-term strontium ranelate administration in monkeys: effects on mineral crystals and on the degree of mineralization of bone. J Bone Miner Res. 2001;16 Suppl 1;401A.
47. Ammann P, Shen V, Robin V. Long-term exposure to strontium ranelate dose-dependently increases bone strenght in intact male and female rats. Osteoporos Int. 2002;13 Suppl 1:24.
48. Reginster JY. Strontium ranelate in osteoporosis. Curr Pharm Des. 2002;8:1907-16.
49. Reginster JY, Roux C, Tsouderos Y. Role of strontium ranelate in prevention of early postmenopausal bone loos: a double-blind, prospective, randomised, placebo-controlled study. Arthrits Rheum. 1998;41 Suppl:580.
50. Reginster JY, Deroisy R, Roux C, Tsouderos Y. Prevention of early postmenopausal bone loos by strontium ranelate a randomized two-year double-blind placebo-controlled trial. J Bone Miner Res. 2001;16 Suppl 1:400F.
51. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis: a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab. 2002;87:2060-6.
52. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459-68.
53. Reginster J-Y, Sawicki A, Devogelaer JP. Strontium ranelate reduces the risk of hip fractures in women with postmenopausal osteoporosis. Osteoporos Int. 2002;13 Suppl 3:10-4.
54. Mosekilde L, Reeve J. Treatment with PTH peptides. Osteoporosis. 2nd ed. New York: Academic Press; 2001. p. 725-46.
55. Hodsman AB. Histopomorphic evidence for increased bone turnover without change in cortical thickness or porosity after two years of cyclic hPTH (1-34) therapy and women with severe osteoporosis. Bone. 2000;27:311-8.
56. Neer R, Arnaud C, Zanchetta JR. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-41.
57. Lindsay R, Scheele WH, Clancy AD. Incident vertebral fractures during an 18 month observation period following discontinuation of LY 333334 (recombinant human -parathyroid hormone (1-34), rhPTH (1-34)) use in -postmenopausal women with osteoporosis. J Bone Miner Res. 2001;16 Suppl:162.
58. Orwoll E, Scheele WH, Clancy AD. Recombinant human parathyroid hormone (1-34) therapy reduces moderate/severe vertebral fracture incidence in men with low bone density. J Bone Miner Res. 2001;16 Suppl:162.
59. Reeve J, Bradbeer JN, Arlot M. hPTH (1-34) treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic, and histological responses. Osteoporos Int. 1991;1:162-70.
60. Lindsay R, Nieves J, Formica C. Randomized controlled study of effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women on estrogen with osteoporosis. Lancet. 1997;350:550-6.
61. Cosman F, Nieves J, Woelfert L. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res. 2001;16:925-31.
62. Neer R, Hayes A, Rao A. Effects of parathyroid hormone, alendronate, or both on bone density in osteoporotic postmenopausal women. J Bone Miner Res. 2002;17 Suppl:135.
63. Black DM, Greenspan SL, Ensrud KE. The effects of -parathyroid hormone alone or in combination in post-menopausal osteoporosis. N Engl J Med. 2003;349:1207-15.
64. Finkelstein JS, Hayes A, Hunzelman JL. The effects of -parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003;349:1216-26.
65. Rittmaster RS, Bolognese M, Ettinger MP. Enhancement of bone mass in osteoporotic women with parathyroid -hormone followed by alendronate. J Clin Endocrinol Metab. 2000;85:2129-34.
66. Ettinger B, San Martin J, Crans GG. Response of markers of bone turnover and bone density to teriparatide in postmenopausal women previously treated with an -antiresorptive drug. J Bone Miner Res. 2003;18 Suppl:15.
67. Hodsman AB, Fraher LJ, Watson PH. A randomized -controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 1997;82:620-8.
68. Vahle JL, Sato M, Long GG. Skeletal changes in rats given daily subcutaneous injections of recombinant human -parathyroid hormone (1-34) for 2 years and relevance to human data. Toxicol Pathol. 2002;30:312-21.